Background: Diabetes is characterized by a nitric oxide de®ciency at the wound site. This study investigated whether exogenous nitric oxide supplementation with the nitric oxide donor molsidomine (N-ethoxycarbomyl-3-morpholinyl-sidnonimine) could reverse the impaired healing in diabetes. Methods: Wound healing was studied by creating a dorsal skin incision with subcutaneous polyvinyl alcohol sponge implantation in diabetic and non-diabetic rats. Half of each group was treated with molsidomine. Collagen metabolism was assessed by wound breaking strength, hydroxyproline (OHP) content, RNA expression for collagen type I and III, and matrix metalloproteinase (MMP) 2 activity in wound sponges. Wound¯uid, plasma and urinary nitric oxide metabolite levels, and the number of in¯ammatory cells were assessed.
Introduction
The problem of impaired healing in diabetes is still not understood. However, all stages of the complex wound healing cascade, including in¯ammation, proliferation, angiogenesis and matrix formation, are impaired. Decreased chemotaxis, phagocytosis, bacterial killing and antioxidant levels 1±3 during the early phase of repair have all been related to impaired healing in diabetes. Growth factor depletion 4, 5 , increased glucocorticoid levels 6 , decreased cell proliferation 7, 8 and upregulation of apoptosis 9 characterize the later phases of healing in diabetics, resulting in poorer granulation tissue formation. Decreased a-actin smooth muscle expression 9 and an excess of adipose tissue 10 may also affect healing in diabetes. Local administration of growth factors has been explored as a potential clinical treatment, but the results have been mostly disappointing. Restoration of blood glucose by insulin partially reverses some of the diabetes-induced wound healing de®ciencies such as restoration of insulin-like growth factor levels, and improvement of bacterial killing and collagen metabolism 11, 12 . Few therapeutic alternatives are therefore available to reverse impaired healing in diabetes.
The role of nitric oxide as a mediator in wound healing has been elucidated recently 13 . Administration of supplemental L-arginine, the sole substrate for inducible nitric oxide synthase (iNOS), improves wound healing 14 , whereas lack of dietary L-arginine delays wound healing in experimental models 15 . Nitric oxide donors increase collagen synthesis in ®broblasts in vitro by an unknown mechanism 16 and accelerate wound closure when applied topically to excisional wounds 17 . Inhibition of iNOS impairs incisional and excisional healing 18, 19 . Equivocal results have been obtained, however, from wound healing experiments in iNOS knockout mice 19, 20 . Although nitric oxide regulates important functions of wound healing, such as cellular proliferation, angiogenesis, chemotaxis and epithelialization 21, 22 , the exact mechanism of action remains unclear.
Based on previous ®ndings that diabetes is characterized by reduced nitric oxide levels in the wound environment 23 , the present study investigated whether exogenous nitric oxide administration can restore the impaired wound healing in experimental diabetes, using molsidomine, a widely used antianginal drug which spontaneously releases nitric oxide.
Materials and methods

Materials
Molsidomine (N-ethoxycarbomyl-3-morpholinyl-sidnonimine) was purchased from Sigma (St Louis, Missouri, USA) and dissolved in ethanol/water (1/99 v/v).
Animals and induction of diabetes
The study was approved by the animal care committee. Male Sprague±Dawley rats (Harlan-Sprague Dawley, Indianapolis, Indiana, USA) were allowed to acclimatize for 1 week and were offered food and water ad libitum throughout the study. Nine days before wounding, 22 rats were injected intraperitoneally with streptozotocin (70 mg per kg body-weight in citrate buffer 0´1 mol/l, pH 4´5) to induce diabetes. Eighteen control rats were injected with citrate buffer only. Induction of diabetes (blood glucose greater 250 mg/dl) was con®rmed by venous glucose measurement. Animals not achieving the diabetic state after 24 h were reinjected with streptozotocin and then excluded from the study if the glucose concentration was not greater than 250 mg/dl.
Half the control and half the diabetic group were treated with molsidomine (1 mg per kg body-weight per day), and the other half received ethanol/water (1/99 v/v) only. The treatment was administered by gavage three times daily in an approximate volume of 2 ml per gavage and started on the day of wounding. All animals were weighed daily and monitored for side-effects.
Wounding
Rats underwent a 7-cm dorsal skin incision and bilateral subcutaneous implantation of polyvinyl alcohol (PVA) sponges (M-PACT, Eudora, Kansas, USA) under intraperitoneal pentobarbital anaesthesia. The incision was closed with surgical staples. Ten days after wounding the rats were killed, blood was obtained by cardiac puncture and the following variables were analysed.
Blood chemistry
Blood glucose, protein, albumin, blood urea nitrogen and creatinine were measured in venous blood.
Urinary nitrate and nitrite
Four to ®ve rats per group were kept in metabolic cages and urine was collected from postoperative day 3 to day 4. Samples were acidi®ed to prevent bacterial overgrowth. Urine samples were analysed for nitrite and nitric oxide metabolite (NO x ) content as described below. Results are expressed as micromoles of NO x per day per rat based on total volume of urine excreted.
Breaking strength
The dorsal skin pelt containing the incision was excised widely and cut by a multibladed guillotine into equal strips, each containing a segment of the healing scar. Immediately after death, four strips from each animal were analysed for wound breaking strength (WBS) using a constant-speed tensiometer.
Hydroxyproline content of sponges
The two most cephaled preweighed sponges were cleared of surrounding granulation tissue and used to measure hydroxyproline (OHP) content (micrograms per 100 mg sponge), an index of collagen deposition, as described previously 24 .
Wound¯uid analysis
Sponges were cleared of surrounding granulation tissue, and wound¯uid was harvested and prepared for NO x measurement as described previously 25 . Arginase activity was quanti®ed spectrophotometrically by urea formation under optimal conditions and expressed as nmoles of urea per minute per milligram protein 26 .
Extraction of wound cellular in®ltrate
Four sponges per animal were use. The squeezed sponges were minced with iris scissors in complete Dulbecco's modi®ed Eagle's medium (DMEM; Gibco Life technologies, Grand Island, New York, USA) containing glutamine, penicillin, streptomycin, fungizone and 1 per cent albumin. The cell suspension was passed through an 80 and 100 stainless steel mesh and combined with the cell pellet from the wound¯uid preparation which was retrieved after the ®rst spin (400g for 10 min). After lysis of red blood cells in ammonium chloride buffer, the cells were washed and counted using a Neubauer chamber. Viability was checked by trypan blue exclusion.
In vitro nitrite synthesis by wound macrophages
Wound cells (1´5 Q 10 6 ) were seeded into 24-well plates (Costar, Cambridge, Massachusetts, USA) in phenol redfree DMEM containing 1 per cent albumin and L-arginine 1 mmol/l, and cultured for 24 h. A macrophage-enriched wound cell population was obtained by vigorously washing off non-adherent cells 2 h after plating. Half of the macrophage-enriched wound cells thus obtained were stimulated with lipopolysaccharide 1 mg/ml and interferon-g 10 units/ml (Boehringer Mannheim, Indianapolis, Indiana, USA). After 24 h the medium was harvested and the cells were lysed for DNA analysis by the Hoechst Dye technique as described previously 27 . Nitrite synthesis values were normalized for DNA concentration. Determination of nitrite was performed using the Griess reagent 28 .
Northern blot analysis
One sponge per animal was used to extract RNA using TRIzol reagent (Gibco Life Technologies) following the manufacturer's instructions. Some 10±15 mg RNA was separated on 1´2 per cent agarose gels, transferred on to nylon membranes (Amersham Life Sciences, Arlington Heights, Illinois, USA) and cross-linked. After prehybridization using salmon sperm DNA, the blots were hybridized at 42°C using mouse collagen types I and III (gift from Dr Ksander, Celltrix, Palo Alto, California, USA) and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probes (generated by polymerase chain reaction). After washing, the blots were autoradiographed. Blots were reprobed with GAPDH to control for equal loading. Densitometry was performed using Image QuantÔ software (Molecular Dynamics Image QuantÔ, Santa Barbara, California, USA). Results are expressed as the ratio of the density for collagen to that for GAPDH; controls were set at 1.
Zymography
The gelatinase activity of equal amounts of wound¯uid proteins ( Table 1) was measured following standard nonreducing sodium dodecyl sulfate±polyacrylamide gel electrophoresis on 7´5 per cent acrylamide gel containing 0´1 per cent gelatin type A as substrate (Fisher, Hampton, New Hampshire, USA), as described previously 29 . The gel was incubated overnight at 37°C in Tris-hydrochloride 50 mmol/l (pH 7´6), sodium chloride 0´2 mol/l, calcium chloride 5 mmol/l and 0´02 per cent (w/v) Brij35, stained in 0´25 per cent coomassie blue and destained.
Statistical analysis
Results are expressed as mean(s.e.m.). Statistical analysis was performed using analysis of variance with Fisher's posthoc test. Signi®cance was reached at P < 0´05. The data were analysed by StatviewÔ programme (Abacus Concepts, Berkeley, California, USA).
Results
Four of the 22 streptozotocin-injected rats did not become diabetic and were excluded. Two other diabetic animals were excluded because gastric gavage was not consistently possible. At the end of the study 18 control and 16 diabetic rats could be evaluated.
Treatment with molsidomine was well tolerated as demonstrated by the equal weight gain in the non-diabetic groups. Treatment with molsidomine resulted in signi®-cantly less weight loss in the diabetic rats (± 4(12) g for molsidomine-treated diabetic rats versus ± 21(7) g for saline-treated diabetic rats; P < 0´05).
Blood glucose values were signi®cantly increased in the diabetic rats, but were not affected by molsidomine treatment ( Table 1) . Wound¯uid protein levels, a re¯ection of the degree of the in¯ammatory response, were signi®-cantly lower in diabetic rats. BUN was also higher in the diabetic animals, most probably indicative of the increased protein catabolism. Molsidomine had no effect on any of these variables.
Molsidomine treatment signi®cantly increased the fresh WBS in the diabetic group but did not affect WBS in the control group. This was paralleled by a signi®cant increase in OHP content with molsidomine in the subcutaneously implanted PVA sponges in both control and diabetic animals ( Table 2) . Diabetic rats had signi®cantly less NO x in wound¯uid than controls indicating a nitric oxide-de®cient state (Fig. 1) . Molsidomine treatment increased NO x excretion in urine, but did not affect NO x levels in wound¯uid or plasma.
Zymograms of wound¯uid, used as an indicator of gelatinase activity, showed signi®cantly less activity in diabetes of an approximately 60-kDa protein, corresponding to MMP-2. Molsidomine treatment speci®cally increased this gelatinase activity in zymograms of control as well as diabetic rats (Fig. 2) .
Northern blot analysis of collagen type I and III gene expression from the sponges showed a 25 per cent decrease in gene expression in the treatment groups compared with controls. Fig. 3 shows one representative northern blot for collagen type I. For densitometry the northern blots were normalized against GAPDH and the non-treated groups were set at 1. Collagen type III gene expression was affected in the same way as collagen type I expression (data not shown).
The in¯ammatory response to wounding, represented by the number of cells isolated per sponge, was signi®cantly decreased in diabetic rats compared with controls (approximately 40 per cent) but was unaffected by molsidomine treatment ( Table 3) . This was con®rmed indirectly by a lower yield of RNA per sponge from the diabetic rats as well as a lower protein concentration in wound¯uid. The ex vivo nitric oxide formation by wound-derived macrophages was approximately equal in all groups as was the increase in nitric oxide synthesis following exposure to lipopolysaccharide and interferon-g (Fig. 4) .
Arginase activity in wound¯uid, representing the alternative pathway of arginine metabolism in wounds, was signi®cantly lower in diabetic wound¯uid (Fig. 5) .
Discussion
The present study con®rms that diabetes is characterized by a nitric oxide-de®cient state accompanied by decreased WBS, collagen deposition and a severely impaired in¯am-matory response. The nitric oxide donor molsidomine Wound¯uid NO x were signi®cantly reduced in diabetic rats compared with controls. Molsidomine treatment did not signi®cantly increase NO x in either wound¯uid or plasma. Urinary NO x production was, however, signi®cantly increased in diabetes possibly re¯ecting activation of the nitric oxide system after induction of diabetes and injury. The volume of urine excreted increased signi®cantly after the induction of diabetes. *P < 0´05 versus control + saline, ²P < 0´05 versus control + molsidomine (analysis of variance with Fisher's posthoc test) represents a potential treatment for acutely impaired healing in diabetes because it increased wound breaking strength by increasing the OHP content of the PVA sponges, a marker of collagen deposition. This nitric oxide donor did not affect collagen gene transcription 16 so a post-transcriptional regulatory mechanism has to be assumed.
The data further show that hyperglycaemia impairs the in¯ammatory response during wound healing as demonstrated by the decreased number of wound in¯ammatory cells in diabetes. Hyperglycaemia and nitric oxide are both known to impair the chemotactic response, but in this study cellular in®ltration was unaffected by nitric oxide donor treatment ( Table 3 ). The reduced in¯ammatory response involves reduced macrophage in®ltration, a process essential for wound healing 30 . As the in vitro nitric oxide synthesis of wound-derived macrophages was no different between control and diabetic rats, the difference in accumulation of nitric oxide metabolites in wound¯uid was rather due to the signi®cantly smaller number of in®ltrating cells. There was also no difference in nitric oxide production after in vitro stimulation of wound-derived macrophages with the cytokine mix. This suggests that in¯ammatory cells in the wound milieu are similarly sensitive to nitric oxide stimulation, although it is not certain that the ex vivo culture of macrophages fully re¯ects in vivo regulation. iNOS synthesis in both control and diabetic macrophages was not fully stimulated indicating that the level of nitric oxide stimulation during wound healing is tightly controlled physiologically.
Nitric oxide donor treatment does not completely restore nitric oxide levels in wound¯uid or plasma (Fig. 1) . The effect of nitric oxide donor administration may be dependent on a threshold rather than a dose. So far, no study has demonstrated a correlation between levels of nitric oxide in wounds and outcome. This corresponds with a previously published study in which administration of nitric oxide donors to ®broblasts induced a signi®cant increase in collagen synthesis within a small range 16 or with the long-lasting effect of a single transfection of iNOS complementary DNA in iNOS knockout mice 25 . It is conceivable that diabetic wounds are more susceptible to nitric oxide donor treatment since the wound is de®cient in nitric oxide. The effect in non-diabetic rats might have been more pronounced if a higher dose of molsidomine was used. The dose chosen was rather low to avoid interference by the vasodilator effect of the nitric oxide donor. Molsidomine has an af®nity for skin tissue 31 which might explain why it affects dermal wound healing with little systemic effect.
Interestingly there was signi®cantly lower arginase activity in wound¯uid from diabetic animals. Arginase is released into wound¯uid by macrophage cell death 32 . Fig. 2 Zymogram of three wound¯uid samples from each group. Equal amounts of protein were loaded on to non-reducing sodium dodecyl sulfate±polyacrylamide gels and analysed as described above. Matrix metalloproteinase (MMP) 2 is an approximately 60-kDa protein (arrow). Diabetic wound¯uids had lower MMP-2 activity than controls. Molsidomine increased MMP-2 activity in control and diabetic animals However, ®broblasts also contribute to wound arginase activity 33 . The reduced arginase activity seems to be speci®c to the wound since liver arginase is upregulated in diabetes 34 . As arginase activity was unaffected by treatment with molsidomine it seems unlikely that this alternative pathway of nitric oxide metabolism is responsible for the effect in the treatment group. WBS, an indicator of the amount and quality of newly deposited collagen at the wound site, was signi®cantly increased by nitric oxide donor treatment in diabetes. This effect was accompanied by increased OHP in the sponges indicating that the nitric oxide donor is probably acting by increasing new collagen formation. Northern blotting, however, revealed no effect of nitric oxide treatment on collagen gene expression. The wound¯uid of diabetic animals had signi®cantly less MMP-2 activity than controls, which was signi®cantly increased by nitric oxide donor treatment (Fig. 2) . MMP-2 originates primarily from ®broblasts and is involved in remodelling of wound healing 35 . Upregulation of MMP-2 might re¯ect increased matrix remodelling by molsidomine treatment.
It has been shown previously that arginine treatment also improves impaired healing in diabetes 36 . That molsidomine treatment modi®es cytokine expression during wound healing and therefore improves collagen synthesis and breaking strength cannot be excluded.
In summary, administration of molsidomine can partially restore the impaired healing in diabetes by enhancing collagen synthesis and WBS. This may have therapeutic potential and needs further clinical evaluation.
